Form 4: Keros Therapeutics Director Buys Shares
Insider Transaction (Form 4)
Jean Jacques Bienaime, a Director of Keros Therapeutics, Inc., purchased 1,000 shares of common stock on July 15, 2026 for $10.61 per share.
Summary
- Open-market purchase: acquired 1,000 Common Stock at $10.61 ($10,610) on July 15, 2026; holds 18,592 after (Direct).
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $10,610, committing personal capital to the stock.
Insider Transactions
Jean Jacques Bienaime — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-15 | Open-market purchase | Common Stock | 1,000 | $11 | $10.6K | 18,592 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-15 | Open-market purchase (1,000 shares) |
Keywords
insider transaction, Form 4, KROS, Keros Therapeutics, Inc., bullish, Jean Jacques Bienaime
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.